Top headlines: Bharat Biotech's Covaxin off trial, IDBI Bank out of PCA

Saudi Aramco's $44-billion refinery project at Nanar in Ratnagiri has become a bone of contention between the Maharashtra government and the Centre

Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode

Bharat Biotech’s Covaxin on Wednesday got the nod from the subject expert committee (SEC), an independent panel set up by the Drugs Controller General of India (DCGI) to advise it, for a restricted emergency use of the Covid-19 vaccine. Covaxin was granted restricted use approval in ‘clinical trial mode’ in January by the DCGI. At that time, the phase 3 trial on 25,800 volunteers was underway. Read more

RBI takes IDBI Bank out of PCA framework after lender improves finances

Private lender IDBI Bank is out of prompt corrective action